Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Feb 21, 2018
Distillery Therapeutics
Cancer
...Phase Ib testing to treat recurrent or refractory metastatic pancreatic cancer. Eli Lilly also has
LY2382770
...
Read More
BioCentury
|
Aug 18, 2016
Distillery Therapeutics
Therapeutics: Transforming growth factor β 1 (TGFB1)
...testing TGFB1 inhibitors in mouse models of other metastatic cancers. Eli Lilly and Co. has
LY2382770
...
Read More
BioCentury
|
Apr 23, 2015
Distillery Therapeutics
Therapeutics: Transforming growth factor (TGF) β
...superfamily, in Phase II testing to treat anemia and thalassemia. Eli Lilly and Co. has
LY2382770
...
Read More
BioCentury
|
Jan 13, 2014
Product Development
Niche play on TGF beta
...effects. Eight companies have candidates in Phase II testing. Eli Lilly and Co. has two:
LY2382770
...
Read More
BioCentury
|
Nov 7, 2013
Distillery Therapeutics
Indication: Infectious disease
...TGFB1 immunomodulator, in Phase II testing to treat multiple sclerosis (MS). Eli Lilly and Co.'s
LY2382770
...
Read More
BioCentury
|
Mar 21, 2013
Targets & Mechanisms
Understanding fibrosis
...Phase II Digna Biotech Disitertide (P144) Dermatology Dermatology Phase II Eli Lilly and Co. (NYSE:LLY)
LY2382770
...
Read More
Items per page:
10
1 - 6 of 6
Previous page
Next page
